Tm Bioscience to use bioMerieux's gene content:
This article was originally published in Clinica
Executive Summary
Tm Bioscience of Toronto, Ontario, has non-exclusively licensed gene content from Marcy l'Etoile, France-based diagnostics firm bioMerieux. The Canadian firm plans to incorporate bioMerieux's patented knowledge of Factor II (prothrombin) and Factor V Leiden genes in its Tag-It mutation detection kits for coagulation disorders, which it launched recently. Tm Bioscience estimates the DNA testing for coagulation disorders in Europe and the US to be growing at more than 50% annually.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.